Skip to main content
. 2017 Jul 25;61(8):e00680-17. doi: 10.1128/AAC.00680-17

TABLE 2.

HBV RNA spliced variants detected in supernatants of infected HepaRG cells treated with and without LMV, as well as patient sera infected with HBV of genotypes A to D

Spliced variant [size of deletion(s) (bp)] No. of sequenced clones containing spliced variantsa
Reference(s)b
HRG-S
Patient samples
Total
DMSO LMV 3.4 3.7 3.56 3.57
Sp1 (1,223) 3 3 3 4 5 8 26 2934, 41
Sp2 (282, 1,223) 0 0 0 4 0 0 4 29, 30
Sp3 (1,602) 5 5 8 0 5 0 23 2931
Sp6 (1,199) 2 1 0 0 0 0 3 2931, 34
Sp7 (455, 684) 1 0 0 0 0 0 1 29, 30
Sp8 (282, 454, 688) 0 0 0 3 0 0 3 29, 30
Sp9 (1,016) 0 0 0 0 0 3 3 29, 30
Sp15 (168, 1,223) 0 0 0 0 1 0 1 29
Sp18 (2,266) 2 0 0 0 0 0 2
Sp19 (2,179) 2 0 0 0 0 0 2
Sp20 (2,290) 1 0 0 0 0 0 1
Sp21 (2,422) 0 3 0 0 0 0 3
Total no. of clones sequenced 16 12 11 11 11 11 72
a

Variants in HepaRG cell supernatants were sequenced from 1.8- and 0.7-kb amplicons; variants in patient samples were sequenced from 1-, 1.5-, and 2-kb amplicons. HepaRG cell samples (HRG-S) were infected with genotype D HBV; patient samples 3.4, 3.7, 3.56, and 3.57 were infected with genotype B, C, D, and A HBV, respectively.

b

The reference(s) for the previously published HBV RNA or DNA variants.